Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1758 1767 1777 1797
This examiner grants 46% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17436218 | IN VIVO REVERSIBILITY OF HIGH MOLECULAR WEIGHT SPECIES | Non-Final OA | AMGEN INC. |
| 17079110 | Genetic Determination of Hormone Levels and Applications Thereof | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 19187629 | BIOMARKER-BASED TREATMENT AND DIAGNOSTIC METHODS FOR IL-17-DEPENDENT CONDITIONS | Final Rejection | MOONLAKE IMMUNOTHERAPEUTICS AG |
| 17633917 | BIOMARKERS FOR NEURODEGENERATIVE DISORDERS | Non-Final OA | The Johns Hopkins University |
| 18027764 | MARKERS FOR DETECTING CARDIOVASCULAR DISEASE AND CARDIOVASCULAR DISEASE RISK | Non-Final OA | The Regents of the University of Michigan |
| 17089448 | Diagnostic Method | Final Rejection | Amazentis SA |
| 17924958 | A Method For Virus and Biomarker Detection | Final Rejection | National University of Singapore |
| 17880676 | TARGET MATERIAL IDENTIFICATION METHOD | Non-Final OA | Taiwan Semiconductor Manufacturing Company, Ltd. |
| 17787015 | ENDOTOXIN DETECTION | Non-Final OA | Eli Lilly and Company |
| 18014582 | ACQUISITION METHOD OF VALUE RELATING TO TRIGLYCERIDE METABOLIC CAPACITY, PRESENTATION METHOD OF DISEASE INFORMATION, PRESENTATION METHOD OF DISEASE DIFFERENTIATION INFORMATION, PRESENTATION METHOD OF THERAPY EFFICACY INFORMATION, PRESENTATION METHOD OF THERAPEUTIC EFFECT INFORMATION, TEST REAGENT AND TEST KIT | Non-Final OA | THE UNIVERSITY OF OSAKA |
| 18023483 | METHODS FOR FINE NEEDLE SAMPLE ANALYSIS VIA MASS SPECTROMETRY | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17816076 | MONITORING AND MANAGEMENT OF CELL THERAPY-INDUCED TOXICITIES | Non-Final OA | Kite Pharma, Inc. |
| 17680195 | BIPHASIC COATINGS WITH CHEMICAL SENSING, AND METHODS OF MAKING AND USING THE SAME | Final Rejection | HRL Laboratories, LLC |
| 17259264 | SUGAR CHAIN SPECIFIC TO PROSTATE CANCER, AND TEST METHOD USING SAME | Non-Final OA | JAPANESE FOUNDATION FOR CANCER RESEARCH |
| 18026088 | METHODS OF DETECTING AND USING BIOMARKERS FOR GLYCOGEN STORAGE DISEASES | Final Rejection | Duke University |
| 17673987 | METHODS AND SYSTEMS FOR EVALUATING ORGANIC CONTAMINANTS IN WATER | Final Rejection | CHEMTREAT, INC. |
| 18147094 | USE OF BIOMARKERS TO DETERMINE SUB-ACUTE TRAUMATIC BRAIN INJURY (TBI) IN A SUBJECT HAVING RECEIVED A HEAD COMPUTERIZED TOMOGRAPHY (CT) SCAN THAT IS NEGATIVE FOR A TBI OR NO HEAD CT SCAN | Non-Final OA | Abbott Laboratories |
| 17766155 | METHOD FOR DETERMINING AN INDIVIDUAL ABILITY TO RESPOND TO A STIMULUS | Final Rejection | UNIVERSITE CLAUDE BERNARD LYON 1 |
| 17027206 | CENTRIFUGE AND METHOD FOR LOADING A DEVICE | Non-Final OA | LIFE TECHNOLOGIES CORPORATION |
| 18763980 | PARTICLES AND METHODS OF ASSAYING | Non-Final OA | Seer, Inc. |
| 18306195 | DETECTION OF AN ANALYTE OF INTEREST BY NANOESI MASS SPECTROMETRY | Final Rejection | Roche Diagnostics Operations, Inc. |
| 16979118 | METHOD FOR ASSISTING DETERMINATION OF RISK OF CARDIOVASCULAR DISEASE OR THE LIKE | Final Rejection | Denka Company Limited |
| 16978959 | DETECTION OF ALZHEIMER'S DISEASE (AD), FRONTOTEMPORAL LOBAR DEGENERATION (FTLD), AMYOTROPHIC LATERAL SCHLEROSIS (ALS), PARKINSON'S DISEASE (PD), AND DEMENTIA WITH LEWY BODIES (DLB) INDICATED BY PHOSPHORYLATION OF MARCKS | Non-Final OA | DENKA COMPANY LIMITED |
| 18634737 | Chronic Disease Management Test to Inform Clinical Care of Patients with Chronic Conditions | Non-Final OA | Aegis Sciences Corporation |
| 16766956 | DETECTION OF BIOMARKERS | Non-Final OA | Imperial College of Science, Technology and Medicine |
| 17907395 | PROGNOSTIC MARKERS OF DISEASE RECURRENCE IN LIVER TRANSPLANT RECIPIENTS WITH HEPATOCELLULAR CARCINOMA | Non-Final OA | Universiteit Gent |
| 16575909 | SYSTEM AND METHOD FOR LIPID QUANTIFICATION | Final Rejection | Waters Technologies Corporation |
| 17760249 | Detection of Lipid Markers | Final Rejection | The University of Manchester |
| 18277424 | IMMUNOLOGICAL ANALYSIS METHOD FOR TYPE-I COLLAGEN C-TERMINAL TELOPEPTIDE | Non-Final OA | SEKISUI MEDICAL CO., LTD. |
| 18011082 | METHOD FOR DETERMINING WHETHER A SUBJECT HAS A DISEASE OR CONDITION OR IS AT RISK OF DEVELOPING A DISEASE OR CONDITION | Non-Final OA | Nightingale Health Oyj |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy